Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Northern Africa

Northern Africa

The Other Vaccines market in Northern Africa is expected to experience significant growth in the coming years.
According to projections, the revenue in this market is set to reach US$146.00m by 2024.
This indicates a promising future for the industry in the region.
Furthermore, it is anticipated that the market will continue to expand at a compound annual growth rate (CAGR) of 10.90% from 2024 to 2029.
This growth trajectory is expected to lead to a market volume of US$244.90m by 2029, showcasing the potential for continued development and expansion in Northern Africa.
When comparing the global market, it is noteworthy that United States is projected to generate the highest revenue in the Other Vaccines market.
In 2024 alone, United States is expected to generate an impressive revenue of US$24,730.00m.
This highlights the dominance of the US market in this market on a global scale.
In Northern Africa, there is a growing demand for other vaccines, driven by an increased focus on preventive healthcare and government initiatives to improve immunization coverage.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Northern Africa is experiencing significant growth due to various factors.

Customer preferences: In Northern Africa, there is a growing trend towards preventive healthcare, which has led to an increased demand for vaccines. Additionally, the rising awareness of the importance of vaccination to prevent diseases has contributed to the growth of the Other Vaccines market.

Trends in the market: The Other Vaccines market in Northern Africa is experiencing a shift towards more innovative and advanced vaccines. There is a growing demand for new vaccines that can combat emerging diseases and provide better protection against existing ones. This trend is driven by the increasing investment in research and development by pharmaceutical companies.

Local special circumstances: Northern Africa is a region that is prone to several infectious diseases, including yellow fever, meningococcal meningitis, and hepatitis A and B. As a result, there is a high demand for vaccines that can protect against these diseases. Additionally, the region has a large population of refugees and migrants, which has led to an increased demand for vaccines to prevent the spread of diseases.

Underlying macroeconomic factors: The Other Vaccines market in Northern Africa is driven by several macroeconomic factors. The region has a growing population, which has contributed to the increasing demand for vaccines. Additionally, the region is experiencing economic growth, which has led to an increase in healthcare spending. This, in turn, has led to an increase in the availability and accessibility of vaccines.In conclusion, the Other Vaccines market in Northern Africa is experiencing significant growth due to the rising demand for vaccines, the shift towards more innovative and advanced vaccines, the high prevalence of infectious diseases, and the region's growing population and economic growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.